| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 393.1 | 357.8 |
| Gross profit | 265.1 | 244.9 |
| Profit before tax | 46.8 | 33.9 |
| Net income | 34.3 | 26.8 |
| EPS (diluted, $ a share) | $0.11 | $0.49 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +28.0% |
|---|---|
| Revenue, year on year | +9.9% |
| Gross margin | 67.4% |
| Operating margin | 7.2% |
10-Q filed with the SEC, NASDAQ: LIVN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
LivaNova PLC: key numbers
- Share price
- $92.44Close, Nov 16
- Market cap
- $5.09B
- Shares outstanding
- 55.09MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Electromedical & Electrotherapeutic ApparatusSIC 3845
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from LivaNova PLC
All →LivaNova CFO Alex Shvartsburg Sells $227K of Stock
Alex Shvartsburg, CFO, sold 2,500 shares of LivaNova PLC at $90.91 a share, worth $227K in total on Nov 12, 2026. Shares held after the trade: 42,147 (-5.6%).
- Value
- $227K
- Shares
- 2,500
- Price
- $90.91
- Role
- CFO
- Holding change
- -5.6%
- Trade date
- Nov 12, 2026
LivaNova Financial Results
LivaNova reported 9.9% revenue growth for the third quarter of 2026, driven by strong demand for its Cardiopulmonary and Epilepsy technologies. The company raised its full-year 2026 constant-currency revenue growth guidance to 9-10% and increased its adjusted diluted EPS outlook. Key operational milestones included the launch of a new oxygenator manufacturing line and the establishment of new CPT codes for its sleep apnea therapy.
- Term
- Q3 2026
“Our team continues to deliver robust revenue growth driven by commercial execution and healthy global demand for our Cardiopulmonary and Epilepsy technologies. We also made meaningful progress against key milestones, positioning us to address significant market demand while expanding patient access to care.”
Vladimir Makatsaria, Chief Executive Officer of LivaNova
LivaNova Insider Francesco Bianchi Sells $273K of Stock
Francesco Bianchi sold 3,500 shares of LivaNova PLC at $78.01 a share, worth $273K in total on Sep 10, 2026. Shares held after the trade: 4,434 (-44.1%).
- Value
- $273K
- Shares
- 3,500
- Price
- $78.01
- Holding change
- -44.1%
- Trade date
- Sep 10, 2026